Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by balmusetteon Jun 06, 2016 1:50pm

271 Views

Post# 24938551

RE:RE:RE:RE:RE:Crazy market

Thank you SPCE01 for taking time to clarify my concern about the validity of the data received concerning Ibalizumab.

I did not think that the FDA checked the clinical trials as a continuous process. I thought that they relied more on trust and maybe spot checks until the end of these trials where then they checked in depth, before giving their final approbation.

If they follow these clinical trials on a continuous basis, then the numbers provided have been validated by an recognized independant organisation outside both companies.

I will look at JFM1330's post as you suggested.

Bullboard Posts

Calibre discovers significant gold in Newfoundland